<SEC-DOCUMENT>0001213900-25-035118.txt : 20250424
<SEC-HEADER>0001213900-25-035118.hdr.sgml : 20250424
<ACCEPTANCE-DATETIME>20250424170003
ACCESSION NUMBER:		0001213900-25-035118
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250424
DATE AS OF CHANGE:		20250424

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINOVAC BIOTECH LTD
		CENTRAL INDEX KEY:			0001084201
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			B9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-79318
		FILM NUMBER:		25868719

	BUSINESS ADDRESS:	
		STREET 1:		NO. 39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085
		BUSINESS PHONE:		86-10-82890088

	MAIL ADDRESS:	
		STREET 1:		NO. 39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NET FORCE SYSTEMS INC
		DATE OF NAME CHANGE:	19991110

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vivo Capital VIII, LLC
		CENTRAL INDEX KEY:			0001618789
		ORGANIZATION NAME:           	
		EIN:				471761992
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		192 LYTTON AVENUE
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
		BUSINESS PHONE:		650 688 0822

	MAIL ADDRESS:	
		STREET 1:		192 LYTTON AVENUE
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Vivo Capital VIII, LLC -->
          <cik>0001618789</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Shares, $0.001 par value per share</securitiesClassTitle>
      <dateOfEvent>04/23/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001084201</issuerCIK>
        <issuerCUSIP>P8696W104</issuerCUSIP>
        <issuerName>Sinovac Biotech Ltd.</issuerName>
        <address>
          <com:street1>No. 39 Shangdi Xi Road</com:street1>
          <com:street2>Haidian District</com:street2>
          <com:city>Beijing</com:city>
          <com:stateOrCountry>F4</com:stateOrCountry>
          <com:zipCode>100085</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Vivo Capital, LLC</personName>
          <personPhoneNum>(650) 688-0818</personPhoneNum>
          <personAddress>
            <com:street1>192 Lytton Avenue,</com:street1>
            <com:city>Palo Alto</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94301</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Stephen Blake</personName>
          <personPhoneNum>650-251-5000</personPhoneNum>
          <personAddress>
            <com:street1>Simpson Thacher &amp; Bartlett LLP</com:street1>
            <com:street2>2475 Hanover Street,</com:street2>
            <com:city>Palo Alto</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94304</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Bryan Jin</personName>
          <personPhoneNum>650-251-5000</personPhoneNum>
          <personAddress>
            <com:street1>Simpson Thacher &amp; Bartlett LLP</com:street1>
            <com:street2>2475 Hanover Street,</com:street2>
            <com:city>Palo Alto</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94304</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001618789</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Vivo Capital VIII, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1360544.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1360544.00</sharedDispositivePower>
        <aggregateAmountOwned>1360544.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>1.9</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>The beneficial ownership reported herein reflects that 1,195,465 of such shares are held by Vivo Capital Fund VIII, L.P. and 165,079 of such shares are held by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.

The beneficial ownership percentage reported herein is based on 71,860,702 common shares outstanding as of March 31, 2024, as reported in the Issuer's Form 20-F filed with the Securities and Exchange Commission on April 29, 2024.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001750698</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Vivo Capital IX, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4539456.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4539456.00</sharedDispositivePower>
        <aggregateAmountOwned>4539456.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>6.3</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>The beneficial ownership reported herein reflects that such shares are held by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

The beneficial ownership percentage reported herein is based 71,860,702 common shares outstanding as of March 31, 2024, as reported in the Issuer's Form 20-F filed with the Securities and Exchange Commission on April 29, 2024.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Shares, $0.001 par value per share</securityTitle>
        <issuerName>Sinovac Biotech Ltd.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>No. 39 Shangdi Xi Road</com:street1>
          <com:street2>Haidian District</com:street2>
          <com:city>Beijing</com:city>
          <com:stateOrCountry>F4</com:stateOrCountry>
          <com:zipCode>100085</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission on July 11, 2018 by Vivo Capital, LLC with respect to the Common Shares, par value $0.001 per share ("Common Shares") of Sinovac Biotech Ltd. (the "Issuer"), Amendment No. 1 thereto filed by Vivo Capital, LLC and Vivo Capital VIII, LLC on July 20, 2018, Amendment No. 2 thereto filed by Vivo Capital, LLC, Vivo Capital VIII, LLC and Vivo Capital IX, LLC on August 27, 2018 and Amendment No. 3 thereto filed by Vivo Capital VIII, LLC and Vivo Capital IX, LLC on March 19, 2025 (as so amended, the "Schedule 13D"). The Items herein amend the information disclosed under the corresponding Items of the Schedule 13D as described herein. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Schedule 13D.</commentText>
      </item1>
      <item4>
        <transactionPurpose>Item 4 is hereby supplemented and amended by adding the following:

On April 23, 2025, Vivo Capital LLC, an affiliate of the Reporting Persons, issued a press release announcing multiple legal proceedings in response to the Issuer's New Board's certain recent actions that have destabilized the Issuer and precipitated a corporate governance crisis.  The press release is attached hereto as Exhibit I and incorporated herein by reference.  The Reporting Persons, and their affiliates, anticipate taking additional legal actions as needed to further protect their rights.</transactionPurpose>
      </item4>
      <item6>
        <contractDescription>Item 6 is hereby supplemented and amended by adding the following:

Item 6 of the Schedule 13D is hereby supplemented and amended to incorporate by reference the information set forth in Item 4 to this Amendment No. 4 to Schedule 13D.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Item 7 is hereby supplemented and amended by adding the following:

Exhibit No.   Description

1                    Press Release dated April 23, 2025*

* Filed herewith</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Vivo Capital VIII, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Dr. Frank Kung</signature>
          <title>Dr. Frank Kung, Managing Member</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Vivo Capital IX, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Dr. Frank Kung</signature>
          <title>Dr. Frank Kung, Managing Member</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>ea023939301ex1-sinovac.htm
<DESCRIPTION>PRESS RELEASE DATED APRIL 23, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vivo Capital Files Lawsuits to Protect Sinovac
Shareholders from the New Board&rsquo;s Value Destructive Actions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Follows Announcement by Sinovac Management Team
That External Auditor Resigned Due to Unreliability of Current Board </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PALO ALTO, Calif.--(BUSINESS
WIRE)--Vivo Capital (&ldquo;Vivo&rdquo; or the &ldquo;Firm&rdquo;), a leading global investment firm focused exclusively on healthcare
and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current Board of Directors
of Sinovac Biotech Ltd. (NASDAQ:SVA) (&ldquo;Sinovac&rdquo; or the &ldquo;Company&rdquo;) under the control of the activist investor 1Globe
Capital LLC (&ldquo;1Globe&rdquo;) and its allies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2025, the Judicial Committee of the Privy Council in London,
England retroactively replaced four members of Sinovac&rsquo;s Board of Directors with individuals nominated by 1Globe in February 2018.
Since then, the new Directors have taken several steps to further 1Globe&rsquo;s interests, entrench their control of the Board, disenfranchise
longtime investors, and destroy shareholder value, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Resisting a sharehloder&rsquo;s request for a special meeting
of shareholders and a Board election;</TD>
</TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.4pt; text-indent: -25.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Announcing an intentionally vague plan of &ldquo;assessing
certain corporate actions taken by the former Board of Directors of the Company after February 2018&rdquo;;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.6pt; text-indent: -25.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">Suggesting potential cancellation of approximately 16% of
Sinovac&rsquo;s common stock that has been held by investors including Vivo since July 2018;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.6pt; text-indent: -25.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Purportedly appointing additional individuals affiliated
with 1Globe and its allies to the Board of Directors; and</TD>
</TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.4pt; text-indent: -25.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Excluding Vivo&rsquo;s Board representative Mr. Shan Fu from
all Board matters.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These actions have destabilized the Company and precipitated a corporate
governance crisis, leading to last week&rsquo;s resignation of Sinovac&rsquo;s independent auditor Grant Thornton Zhitong Certified Public
Accountants LLP (&ldquo;Grant Thornton&rdquo;). As the Company&rsquo;s management team disclosed on April 22, 2025, in a statement, the
auditor resigned because it could no longer rely on prior Board resolutions and management representations in auditing the Company&rsquo;s
financials and issuing its opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has not been able to secure a replacement auditor, which
not only delays a potential resumption of Sinovac&rsquo;s common stock trading on the NASDAQ exchange&mdash;it has been halted since 2019&mdash;but
also jeopardizes the Company&rsquo;s ability to comply with U.S. securities laws and maintain its NASDAQ public company status. In contrast,
Vivo appreciates that Sinovac&rsquo;s management team is prioritizing the best interests of all shareholders and agrees with its call
for a special meeting to elect a new Board to help lead the company forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To protect the interests of the Company and all Sinovac shareholders,
and to prevent further destructive actions by 1Globe and its Board representatives, Vivo Capital has initiated multiple legal proceedings,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: left">A lawsuit against Sinovac in the Antigua and Barbuda High
Court of Justice, challenging the validity of the illegal actions of the 1Globe-affiliated Directors;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.6pt; text-indent: -25.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: left">A lawsuit against the 1Globe-affiliated Directors in the
Supreme Court of the State of New York for the egregious breaches of the fiduciary duties they owe to Sinovac; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.6pt; text-indent: -25.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: left">A federal lawsuit against 1Globe in the U.S. District Court
for the District of Massachusetts, seeking a court order enjoining 1Globe from further violating U.S. securities laws and compelling
it to disclose its plans and proposals regarding Sinovac.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vivo calls on other Sinovac shareholders to support its fight against
the irresponsible actions of 1Globe and its affiliated Board representatives. Vivo also urges 1Globe and its Board representatives to
engage in discussions with the Firm and other concerned shareholders to resolve these issues as soon as possible so that the Company can
focus on its missions and objectives, and to operate the company for the benefit of all Sinovac shareholders and the general public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Vivo Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Founded in 1996, Vivo Capital is a leading global healthcare investment
firm with a diverse, multi-fund investment platform spanning venture capital, growth equity, buyout, and public equities. The Firm has
approximately $5.3 billion in regulatory assets under management and has invested in over 430 public and private companies globally. Headquartered
in Palo Alto, California, the Vivo team consists of more than 75 multi-disciplinary professionals. Vivo invests broadly in healthcare
across multiple sub-sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest
healthcare markets globally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media<BR>
Prosek Partners<BR>
Pro-Vivo@Prosek.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
